Imaging therapy response and failure
Erik Sahai, The Francis Crick Institute, London
Many tumors show an initial response to targeted therapies before genetic resistance emerges, however little is known about how tumor cells tolerate therapy before genetic resistance dominates. We present data that shows how the ECM generates a ‘safe haven’ in which melanoma cells can tolerate targeted therapy. This supports the population of cancer cells from which genetically resistance emerges. We are now studying the emergence of resistant clones and clonal competition in the context of ‘safe havens’. Finally, we present analysis of organ specific responses to targeted therapy in melanoma.